Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

References

• Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489–496.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–1580.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–1028.
   PubMed Web of Science ®Google Scholar
• Dayama A, Dass J, Seth T, et al. Clinico-hematological profile and outcome of acute promyelocytic leukemia patients at a tertiary care center in North India. Indian J Cancer. 2015;52(3):309–312.
   PubMed Web of Science ®Google Scholar
• Bajpai J, Sharma A, Kumar L, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in North India. Indian J Cancer. 2011;48(3):316–322.
   PubMed Web of Science ®Google Scholar
• Kapoor J, Mirgh SP, Agrawal N, et al. High risk acute promyelocytic leukemia – an enigma for hematologists: optimizing treatment with APML-4 protocol. Indian J Hematol Blood Transfus. 2022;38(2):394–402.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
   PubMed Web of Science ®Google Scholar
• Varma S, Yanamandra U, Khadwal A, et al. Paper: high risk Apml treated successfully with four cycles of ATO and ATRA combination in resource constrained settings. 57th Annual Meeting & Exposition, ASH; 2015.
   Google Scholar
• Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis. 2011;3(1):e2011059.
   PubMedGoogle Scholar
• Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015–3012.
   PubMed Web of Science ®Google Scholar
• de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–3402.
   PubMed Web of Science ®Google Scholar
• Rahmé R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–2424.
   PubMed Web of Science ®Google Scholar
• Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108(4):689–695.
   PubMed Web of Science ®Google Scholar
• McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–136.
   PubMed Web of Science ®Google Scholar
• Jácomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–1432.
   PubMed Web of Science ®Google Scholar
• Österroos A, Maia T, Eriksson A, et al. A real-world based score to predict early death in acute promyelocytic leukemia. Haematology. 2022;107(7):1528–1537.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Deneberg S, Antunovic P, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013. Leukemia. 2017;31(6):1457–1459.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–4725.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008;112(8):3130–3134.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Italian GIMEMA cooperative group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171–3179.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015;168(5):646–653.
   PubMed Web of Science ®Google Scholar
• Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227–234.
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Rodriguez I, Kantarjian H, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. 2015;56(5):1342–1345.
   PubMed Web of Science ®Google Scholar